Document is current
Any future updates will be listed below
-
Authors
McThenia, Sheila S.
Pandit-Taskar, Neeta
Grkovski, Milan
Donzelli, Maria A.
Diagana, Safiatu
Greenfield, Jeffrey P.
Souweidane, Mark M.
Kramer, Kim https://orcid.org/0000-0002-3803-878X
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
- License Information
-
More Information
Article History
Received: 18 January 2022
Accepted: 17 March 2022
First Online: 11 April 2022
Declarations
:
: Kim Kramer discloses paid consulting for and holding equity in YmAbs Therapeutics, Inc. Kim Kramer also discloses expert testimony (Tydings) and patents pending. N. Pandit-Taskar has served as a consultant for or been on an advisory board and has received honoraria for Actinium Pharma, Progenics, Medimmune/Astrazeneca, Illumina, ImaginAb, and conducts research institutionally supported by Ymabs, ImaginAb, BMS, Bayer, Clarity pharma, Janssen and Regeneron. The remaining authors declare no competing financial interests.
